Cargando…
AstraZeneca COVID-19 vaccine: no increased rate of VTE
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035882/ http://dx.doi.org/10.1007/s40278-021-93813-z |
Ejemplares similares
-
AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021) -
AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021) -
Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021) -
Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
Publicado: (2021) -
Lipschütz ulcers after AstraZeneca COVID-19 vaccination()
por: Bracho-Borro, Maria, et al.
Publicado: (2023)